JP2021516254A5 - - Google Patents

Info

Publication number
JP2021516254A5
JP2021516254A5 JP2020560859A JP2020560859A JP2021516254A5 JP 2021516254 A5 JP2021516254 A5 JP 2021516254A5 JP 2020560859 A JP2020560859 A JP 2020560859A JP 2020560859 A JP2020560859 A JP 2020560859A JP 2021516254 A5 JP2021516254 A5 JP 2021516254A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antibody according
sialyl
stn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516254A (ja
JP7324777B2 (ja
Filing date
Publication date
Priority claimed from PT110526A external-priority patent/PT110526B/pt
Application filed filed Critical
Publication of JP2021516254A publication Critical patent/JP2021516254A/ja
Publication of JP2021516254A5 publication Critical patent/JP2021516254A5/ja
Application granted granted Critical
Publication of JP7324777B2 publication Critical patent/JP7324777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560859A 2018-01-26 2019-01-17 腫瘍抗原に対するl2a5抗体またはその機能的断片 Active JP7324777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT110526A PT110526B (pt) 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
PT110526 2018-01-26
PCT/PT2019/000001 WO2019147152A1 (en) 2018-01-26 2019-01-17 L2a5 antibody or functional fragment thereof against tumour antigens

Publications (3)

Publication Number Publication Date
JP2021516254A JP2021516254A (ja) 2021-07-01
JP2021516254A5 true JP2021516254A5 (https=) 2022-02-24
JP7324777B2 JP7324777B2 (ja) 2023-08-10

Family

ID=65244573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020560859A Active JP7324777B2 (ja) 2018-01-26 2019-01-17 腫瘍抗原に対するl2a5抗体またはその機能的断片

Country Status (14)

Country Link
US (1) US11353460B2 (https=)
EP (1) EP3743726B1 (https=)
JP (1) JP7324777B2 (https=)
CN (1) CN113287018B (https=)
AU (1) AU2019211035B2 (https=)
BR (1) BR112020014931A2 (https=)
CA (1) CA3089300A1 (https=)
EA (1) EA202091760A1 (https=)
IL (1) IL276208B1 (https=)
MX (1) MX2020007828A (https=)
PT (1) PT110526B (https=)
SG (1) SG11202006897VA (https=)
WO (1) WO2019147152A1 (https=)
ZA (1) ZA202005023B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022195797A1 (ja) * 2021-03-18 2022-09-22 国立大学法人弘前大学 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法
WO2022224242A1 (en) * 2021-04-20 2022-10-27 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
GB2619976A (en) * 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
CN121219019A (zh) 2023-05-05 2025-12-26 百欧恩泰欧洲股份公司 用于增强靶向癌症相关抗原的采用新型连接子-有效载荷系统的抗体药物偶联物
WO2026057354A1 (en) * 2024-09-10 2026-03-19 Invox Pharma Limited Anti-sialyl-tn antigen-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE68922806T2 (de) * 1988-03-11 1996-02-29 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten.
WO1995029927A2 (en) 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1998046246A1 (en) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
JP3809277B2 (ja) 1998-03-05 2006-08-16 生化学工業株式会社 N−アセチルグルコサミン−6−o−硫酸基転移酵素のポリペプチド及びそれをコードするdna
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
EP2261255A1 (en) 2003-07-15 2010-12-15 The Regents of The University of California Methods for purifying sialic acid-specific antibodies and composition comprising affinity-purified antibodies
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
AU2007304590A1 (en) 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
JP5156887B2 (ja) * 2007-02-14 2013-03-06 独立行政法人科学技術振興機構 2−6シアリル6−スルホ糖鎖に対する抗体
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
EP2524233A4 (en) 2010-01-15 2013-07-31 Univ California COMPOSITIONS AND METHOD FOR DETECTING CANCER
US9796785B2 (en) 2013-05-02 2017-10-24 National Institute Of Advanced Industrial Science And Technology Monoclonal antibody recognizing sialylated sugar chains
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016057916A1 (en) * 2014-10-10 2016-04-14 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017040529A1 (en) * 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors
WO2018217116A1 (en) * 2017-05-25 2018-11-29 Instituto De Patologia E Imunologia Da Universidade Do Porto (Ipatimup) Detection and isolation of cancer cells from body fluids based on a glycosylation pattern and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021516254A5 (https=)
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2020522261A5 (https=)
JP2020500003A5 (https=)
JP2006020633A (ja) 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
JP2016516400A5 (https=)
IL265434B1 (en) Anti-cd27 antibodies
JP2021500916A5 (https=)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2023540526A5 (https=)
WO2023130123A2 (en) Bispecific sars-cov-2 antibodies and methods of use
JP2021517459A5 (https=)
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
RU2020113713A (ru) Слитый белок, содержащий молекулу fgf-18
JP2018515071A5 (https=)
CN109867723B (zh) 抗人il6单克隆抗体及其制备方法和用途
JP2016536988A5 (https=)
CN109021103B (zh) 抗人血管内皮生长因子的抗体及其制备方法和应用
JP2021525512A5 (https=)
JP2020521752A (ja) グロボhに対するヒト化抗体および癌治療におけるその使用
CN113651884A (zh) 人源化抗SARS-CoV-2单克隆抗体及其应用
CN115850477B (zh) 一种抗人4-1bb单克隆抗体及其应用
CN110642947A (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用